8MM HER2-Negative Breast Cancer Epidemiology Forecast Report 2024-2034 Gain Age, Hormone Status, And Stage Insights For Strategic Planning

(MENAFN- GlobeNewsWire - Nasdaq) Explore the comprehensive "HER2-Negative Breast Cancer: Epidemiology Report and Model," covering risk factors, trends, and forecasts in major markets. Gain insights into global HER2- breast cancer cases segmented by age, hormone status, and stage, aiding strategic planning for therapeutics and market growth.

Dublin, Sept. 08, 2025 (GLOBE NEWSWIRE) -- The "HER2-Negative Breast Cancer: Epidemiology Forecast to 2034" report has been added to ResearchAndMarkets's offering.

HER2-Negative Breast Cancer: Epidemiology Report and Model provide an overview of the risk factors, comorbidities, and the global and historical trends of HER2-negative (HER2-) breast cancer in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban China).

The report includes a 10-year epidemiology forecast for the diagnosed incident cases of all invasive breast cancer, diagnosed incident cases of HER2- breast cancer, and five-year diagnosed prevalent cases of HER2- breast cancer. The diagnosed incident cases of all invasive breast cancer among women are segmented by age (18 years and older), and hormone receptor (HR) status (HER2-/HR+ and HER2-/HR-).

The diagnosed incident cases of HER2- breast cancer among women are segmented by stage at diagnosis (stages I, II, I-II, III, and IV). Five-year diagnosed prevalent cases of invasive HER2- breast cancer are segmented by progression to metastatic disease; stage (stages I-II, III, and IV); menopausal status (HER2-/HR+ only); tumor resection; HR positivity (HER2-/HR+ only); mutations and biomarkers; and other HER2 activating mutations.

According to the World Health Organization (WHO), breast cancer was the most common diagnosed cancer in women in 157 out of 185 countries in 2022 and is the leading cause of cancer death in women globally (IARC, 2020; WHO, 2024). Risk factors include prolonged exposure to endogenous/exogenous sex hormones; gene mutations; a family history of breast cancer; being overweight or obese; physical inactivity; high alcohol consumption; early menarche; late menopause; and clinical factors, such as biopsy-confirmed atypical hyperplasia and having a high breast tissue and bone density (IARC, 2020; American Cancer Society, 2022).
HER2- breast cancer Epidemiology series will allow you to:

• Develop business strategies by understanding the trends shaping and driving the global HER2- breast cancer markets.
• Quantify patient populations in the global HER2- breast cancer markets to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups, HER2- subtypes, breast cancer stages, and genetic groups that present the best opportunities for HER2- breast cancer therapeutics in each of the markets covered.
• Understand magnitude of the HER2- breast cancer population by age, HR status, stage, tumor resection and genetic groups.

Key Topics Covered:

1 HER2-Negative (HER2-) Breast Cancer: Executive Summary
1.1 Catalyst
1.2 Related reports
1.3 Upcoming reports
2 Epidemiology
2.1 Disease background
2.2 Risk factors and comorbidities
2.3 Global and historical trends
2.4 8MM forecast methodology
2.4.1 Sources
2.4.2 Forecast assumptions and methods
2.4.3 Forecast assumptions and methods: diagnosed incident cases of all invasive breast cancer and HER2- breast cancer
2.4.4 Forecast assumptions and methods: diagnosed incident cases of invasive HER2- breast cancer by stage at diagnosis
2.4.5 Forecast assumptions and methods: five-year diagnosed prevalent cases of invasive HER2- breast cancer
2.4.6 Forecast assumptions and methods: five-year diagnosed prevalent cases of invasive HER2- breast cancer by stage
2.4.7 Forecast assumptions and methods: five-year diagnosed prevalent cases of invasive HER2- breast cancer with progression to metastatic disease
2.4.8 Forecast assumptions and methods: five-year diagnosed prevalent cases of invasive HER2-/HR+ breast cancer by menopausal status
2.4.9 Forecast assumptions and methods: five-year diagnosed prevalent cases of invasive HER2- breast cancer with resectable tumors
2.4.10 Forecast assumptions and methods: five-year diagnosed prevalent cases of invasive HER2-/HR+ breast cancer by HR positivity
2.4.11 Forecast assumptions and methods: five-year diagnosed prevalent cases of invasive HER2- breast cancer by mutations and biomarkers
2.4.12 Forecast assumptions and methods: diagnosed five-year diagnosed prevalent cases of invasive HER2- breast cancer with other HER2 activating mutations
2.5 Epidemiological forecast for invasive HER2- breast cancer (2024-34)
2.5.1 Diagnosed incident cases of all invasive breast cancer
2.5.2 Age-specific diagnosed incident cases of all invasive breast cancer
2.5.3 Diagnosed incident cases of invasive HER2-/HR+ breast cancer
2.5.4 Diagnosed incident cases of invasive HER2-/HR- breast cancer
2.5.5 Diagnosed incident cases of invasive HER2-/HR+ breast cancer and invasive HER2-/HR- breast cancer by stage at diagnosis
2.5.6 Five-year diagnosed prevalent cases of invasive HER2-/HR+ breast cancer
2.5.7 Five-year diagnosed prevalent cases of invasive HER2-/HR- breast cancer
2.5.8 Five-year diagnosed prevalent cases of invasive HER2- breast cancer by stage
2.5.9 Five-year diagnosed prevalent cases of invasive HER2- breast cancer with progression to metastatic disease
2.5.10 Five-year diagnosed prevalent cases of invasive HER2-/HR+ breast cancer by menopausal status
2.5.11 Five-year diagnosed prevalent cases of invasive HER2-/HR+ and HER2-/HR- breast cancer by resectable tumors
2.5.12 Five-year diagnosed prevalent cases of invasive HER2-/HR+ breast cancer by HR positivity
2.5.13 Five-year diagnosed prevalent cases of invasive HER2- breast cancer by mutations and biomarkers
2.5.14 Five-year diagnosed prevalent cases of invasive HER2- breast cancer with other HER2 activating mutations
2.6 Discussion
2.6.1 Epidemiological forecast insight
2.6.2 Limitations of the analysis
2.6.3 Strengths of the analysis
3 Appendix
For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN08092025004107003653ID1110031900